35Pharma's lead development programme is HS235, an activin receptor-targeting fusion protein that has completed phase 1 ...

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 ...

Some processes have plagued the research industry for decades. They’re inefficient and unpopular, but somehow resistant to ...

While Vir Biotech is best known for its work on infectious diseases, its developing cancer pipeline has delivered a partnership with Astellas that could be worth around $1.4 billion.

Novo Nordisk launched an oral formulation of its peptide-based GLP-1 agonist Wegovy (semaglutide) in the US a few weeks ago, claiming a lead in a category that until then was made up mainly by ...

On today’s podcast, Jonah Comstock is joined by Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy ...

Reimbursement authority NICE has said that Incyte's JAK inhibitor cream Opzelura (ruxolitinib) can be used to treat people ...

The new oncology division will be run by Jannie Oosthuizen, previously head of Merck Human Health US, while the non-oncology ...

The results in a Chinese population living with obesity are the first major readout for UBT251, a 'triple G' agonist of the ...

The changes to the Quality and Outcomes Framework (QOF) incentive programme mean that GPs will be able to receive up to £3,000 per year for Mounjaro (tirzepatide) prescriptions and another £1,000 for ...

The final piece of this evolution comes from closing the loop between AI scientists and the physical laboratory. In 2026, AI systems will connect seamlessly with robotic laboratories, creating true ...

Gilead Sciences has shored up its position in cell therapies for cancer with a deal to acquire Arcellx, a company it has been ...